Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
128.9 USD | +0.05% | -1.55% | +18.05% |
05:02pm | Merck: encouraging results in gastric cancer | CF |
May. 01 | Merck Says Keytruda Meets Primary Endpoint in Late-Stage Gastric Cancer Trial | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.05% | 326B | |
+30.81% | 699B | |
+25.07% | 571B | |
-4.79% | 364B | |
+2.85% | 286B | |
+14.68% | 236B | |
+4.71% | 198B | |
-12.43% | 194B | |
-4.50% | 154B | |
-4.12% | 149B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Merck Says Health Canada Approved Keytruda Plus Fluoropyrimidine, Platinum-Containing-Chemotherapy for Gastric Cancer